ADAR1 Capital Management’s enGene Therapeutics ENGN Stock Holding History

ADAR1 Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$910K	Sell	133,686 -170,000	-56%	-$1.51M	0.05%	167
2025 Q4	$2.74M	Buy	+303,686	New	+$2.43M	0.2%	87
2025 Q3	–	Sell	-27,787	Closed	-$101K	–	236
2025 Q2	$101K	Buy	27,787 +3,988	+17%	+$15K	0.02%	175
2025 Q1	$107K	Buy	+23,799	New	+$148K	0.02%	163
2024 Q4	–	Sell	-1,970	Closed	-$13K	–	241
2024 Q3	$13K	Buy	1,970 +1,370	+228%	+$10.2K	﹤0.01%	250
2024 Q2	$5.66K	Buy	+600	New	+$7.7K	﹤0.01%	240

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ADAR1 Capital Management's ENGN Position: Q1 2026 in Review

ADAR1 Capital Management reduced its enGene Therapeutics (ENGN) stake by 56% in Q1 2026, selling an estimated $1.51M and leaving 133,686 shares worth $910K. The position accounts for 0.05% of the portfolio, ranked #167.

ADAR1 Capital Management first reported a position in ENGN in Q2 2024 and has held it in 6 quarters since. The position peaked at $2.74M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

ADAR1 Capital Management held 133,686 shares of enGene Therapeutics worth $910K as of Q1 2026.
ADAR1 Capital Management sold 170,000 enGene Therapeutics shares in Q1 2026, an estimated $1.51M.
enGene Therapeutics made up 0.05% of ADAR1 Capital Management's portfolio in Q1 2026, its #167 holding.
ADAR1 Capital Management first reported a position in enGene Therapeutics in Q2 2024 and has held it in 6 quarters since.
ADAR1 Capital Management's enGene Therapeutics position peaked at $2.74M in Q4 2025.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.